Jupiter Neurosciences Inc(JUNS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -19.11 | Insider Own | 31.06% | Shs Outstand | 1.3M | Perf Week | -8.14% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.9M | Perf Month | -2.87% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.25% | Short Float | 4.24% | Perf Quarter | -64.89% |
| Income | -0.01B | P/S | 52.14 | EPS this Y | - | Inst Trans | 16.15% | Short Ratio | 0.04 | Perf Half Y | -91.67% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -239.36% | Short Interest | 0.04M | Perf YTD | -96.9% |
| Book/sh | -0.55 | P/C | 2.06 | EPS past 3/5Y | -18.3% -7.78% | ROE | -1888.7% | 52W High | -98.14% ($127.49) | Perf Year | -97.79% |
| Cash/sh | 1.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5.29% ($2.25) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -43.11% | Gross Margin | 81.8% | Volatility(W/M) | 13.35% 11.73% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 56.47 | Sales Y/Y TTM | - | Oper. Margin | -15166.68% | ATR (14) | 0.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.62 | EPS Q/Q | 19.9% | Profit Margin | -14220.12% | RSI (14) | 36.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.66 | Sales Q/Q | - | SMA20 | -15.64% ($2.81) | Beta | 1.87 | Target Price | $1875 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -26.54% ($3.23) | Rel Volume | 0.01 | Prev Close | $2.5 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -88.63% ($20.84) | Avg Volume(3M) | 0.89M | Price | $2.37 |
| IPO | 2024/12/3 | Option/Short | No/Yes | Trades | 426 | Volume | 7,416 | Change | -5.2% |
🧠 Jupiter Neurosciences is a clinical-stage biotech company targeting central nervous system (CNS) disorders with JOTROL™, its patented micellar delivery platform for resveratrol. The company highlights over 9x higher bioavailability compared to conventional resveratrol and is expanding into rare CNS indications such as Parkinson's disease, Alzheimer's, Friedreich's ataxia, and MELAS. Using the same technology, it also operates the Nugevia™ nutraceutical brand.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
JUNS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,214. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #560 of 594 in the industry
Based on market cap of $3M.
JUNS#560 Jupiter Neurosciences Inc $3M PER - 
ADXN#561 Addex Therapeutics Ltd ADR $3M PER - 
ONCO#562 Onconetix Inc $3M PER - 
MBIO#563 Mustang Bio Inc $3M PER - 
CMND#564 Clearmind Medicine Inc $3M PER - 
FAQ
What kind of company is JUNS?
JUNS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JUNS?
The market cap of JUNS is approximately $3M, ranking 5,727 within its sector.
What is the 52-week high and low for JUNS?
JUNS has recorded a 52-week high of $127.49 and a low of $2.25.
